Please use this identifier to cite or link to this item:
Title: Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
Austin Authors: Fernando, Dinali H;Forbes, Josephine M;Angus, Peter W ;Herath, Chandana B
Affiliation: Department of Medicine, The University of Melbourne, Melbourne, Australia
Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
Mater Institute, University of Queensland, Brisbane, Australia
Issue Date: 11-Oct-2019 2019-10-11
Publication information: International journal of molecular sciences 2019; 20(20): E5037
Abstract: Non-alcoholic fatty liver disease (NAFLD) affects up to 30% of the adult population and is now a major cause of liver disease-related premature illness and deaths in the world. Treatment is largely based on lifestyle modification, which is difficult to achieve in most patients. Progression of simple fatty liver or steatosis to its severe form non-alcoholic steatohepatitis (NASH) and liver fibrosis has been explained by a 'two-hit hypothesis'. Whilst simple steatosis is considered the first hit, its transformation to NASH may be driven by a second hit. Of several factors that constitute the second hit, advanced glycation end products (AGEs), which are formed when reducing-sugars react with proteins or lipids, have been implicated as major candidates that drive steatosis to NASH via the receptor for AGEs (RAGE). Both endogenous and processed food-derived (exogenous) AGEs can activate RAGE, mainly present on Kupffer cells and hepatic stellate cells, thus propagating NAFLD progression. This review focuses on the pathophysiology of NAFLD with special emphasis on the role of food-derived AGEs in NAFLD progression to NASH and liver fibrosis. Moreover, the effect of dietary manipulation to reduce AGE content in food or the therapies targeting AGE/RAGE pathway on disease progression is also discussed.
DOI: 10.3390/ijms20205037
PubMed URL: 31614491
Type: Journal Article
Subjects: advanced glycation end products
hepatic Kuppfer cells
hepatic stellate cells
non-alcoholic fatty liver disease
oxidative stress
receptor for advanced glycation end products
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 28, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.